Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS-2 olverembatinib in chronic phase chronic myeloid leukemia
2024-511495-32-00Phase 3Authorised
- Sponsor
- Ascentage Pharma
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of olverembatinib and bosutinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Ascentage Pharma. Primary endpoints: Major molecular response rate at 24 weeks and Major molecular response rate by 24 weeks. Planned start Apr 2025; status: authorised.
02
Drugs
olverembatinibbosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-511495-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511495-32-00.